[Form 4] Alaunos Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Holger Weis, Chief Executive Officer and Director of Alaunos Therapeutics, Inc. (TCRT), exercised employee stock options to acquire 13,676 shares on 08/18/2025. The exercised options carry a $2.32 per-share exercise price and are fully vested as of the transaction date, resulting in 13,676 shares beneficially owned by Mr. Weis following the transaction. The Form 4 was signed and dated 08/20/2025 by the reporting person. The filing shows an acquisition via option exercise rather than an open-market purchase and does not report any dispositions or other classes of securities.

Positive

• CEO increased beneficial ownership by acquiring 13,676 shares through exercise, aligning management interests with shareholders
• Options were fully vested at the time of exercise, indicating no acceleration or special vesting treatment

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Insider exercise increased CEO ownership modestly; routine executive equity activity that signals alignment but is not strategically material.

The Form 4 documents a standard, fully vested employee stock option exercise by the CEO and director, yielding 13,676 additional common shares at a $2.32 exercise price. From a governance perspective, exercises of vested options are common compensation events and reinforce management ownership alignment with shareholders. The filing contains no indications of unusual timing, related-party transfers, or sales that would raise governance flags. Impact on control or dilution is immaterial given the single-class, single-person nature of the transaction.

Securities Analyst

TL;DR: This is a routine exercise of vested options by the CEO; it modestly increases insider holdings but is unlikely to be market-moving.

The transaction adds 13,676 shares to the CEO's holdings via exercise at $2.32 per share. The exercise price and the fact the options were fully vested are explicitly disclosed. There are no reported dispositions or sales that would signal liquidity-driven selling by the insider. For investors, the event shows insider participation in equity but does not provide new operational or financial information about company performance or prospects.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weis Holger

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD., SUITE 300

(Street)

FORT LAUDERDALE FL 33301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.32	08/18/2025		A		13,676		(1)	08/17/2035	Common Stock	13,676	$0	13,676	D

Explanation of Responses:

1. These options are fully vested as of August 18, 2025.

	/s/ Holger Weis	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Holger Weis report on the Form 4 for TCRT?

Holger Weis reported exercising employee stock options to acquire 13,676 shares of Alaunos Therapeutics common stock on 08/18/2025.

How many shares did the insider acquire and at what price?

13,676 shares were acquired by exercise at an exercise price of $2.32 per share.

Were the options vested at the time of the transaction?

Yes. The Form 4 states the options were fully vested as of August 18, 2025.

Did the Form 4 report any sales or dispositions by the reporting person?

No. The filing reports an acquisition via exercise and does not disclose any dispositions or open-market sales.

When was the Form 4 signed and filed?

The signature date on the form is 08/20/2025 signed by Holger Weis; the transaction date reported is 08/18/2025.